Not Just “COVID Anxiety”: A Case of Subacute Thyroiditis in a Patient Recovering From SARS-CoV-2 Infection

Hameed Ullah 1, Ijaz Ali 1, Fazal Alam 2, Wajid Ali 1, Masroor Anwar 2

1. Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK
2. Internal Medicine, Khyber Teaching Hospital, Peshawar, PAK

Corresponding author: Hameed Ullah, drhameed1995@gmail.com

Abstract
Subacute thyroiditis (SAT) is an uncommon, granulomatous, inflammatory thyroid disorder. It usually presents with anterior neck and/or jaw pain, diffusely tender goiter, fever, fatigue, myalgia, and anorexia. The thyroid gland is diffusely or asymmetrically swollen and tender. Almost 60% of the patients develop symptoms and signs of hyperthyroidism which usually subsides within a few weeks with or without going through a transient phase of hypothyroidism. We report a case of SAT in a 30-year-old male who was recovering from a mild SARS-CoV-2 infection.

Case Presentation
A previously healthy, 30-year-old male presented to the ED with a three days history of pain in the anterior neck and chin, palpitations, and anxiety. The patient revealed that 16 days ago, he was diagnosed with COVID-19 infection following his visit to the hospital due to complaints of fever and generalized body aches. His infection was mild and did not need any treatment apart from as-needed paracetamol. He was making an uneventful recovery until three days ago, when he developed these symptoms. He went to a nearby clinic, where he was reassured that "COVID anxiety" was the cause of his symptoms.

On examination, the patient was found to have tachycardia (heart rate = 134 bpm), a blood pressure of 131/73 mm Hg, oxygen saturation of 98% on room air, and a random blood glucose level of 97 mg/dL. He had warm, sweaty palms and an exquisitely tender neck mass consistent with a diffusely swollen thyroid gland (Figure 1). No lymphadenopathy was observed. The rest of the examination was unremarkable. Laboratory investigations showed severely decreased serum thyroid-stimulating hormone (TSH) levels and highly elevated levels of serum T3 and T4. ECG showed sinus tachycardia. Along with lymphocytic leucocytosis, the elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) was also noted. Key laboratory values are summarised in Table 1. Ultrasonography of the neck showed diffuse enlargement, hypoechoicinity, and decreased vascularity of the thyroid gland on color Doppler. Due to high clinical suspicion of SAT, a radionuclide thyroid scan was deferred.

Introduction
Subacute thyroiditis (SAT) is an uncommon cause of hyperthyroidism [1]. The most common presenting symptom is anterior neck pain [2]. Other common symptoms include fever, fatigue, anorexia, myalgia, and malaise [1]. The thyroid gland is diffusely or asymmetrically swollen and tender. Almost 60% of the patients develop symptoms and signs of hyperthyroidism [3]. The disease is usually self-limited and follows a predictable course of hyperthyroidism followed by a transient phase of hypothyroidism. Most patients achieve a euthyroid state within two to four months; however, a subset of the patients can develop a chronic state of hypothyroidism [2]. We report a case of SAT in a 30-year-old male who was recovering from a mild SARS-CoV-2 infection.
FIGURE 1: The swollen thyroid gland on initial presentation.

| Test               | Results | Normal values  |
|--------------------|---------|----------------|
| Hemoglobin         | 12.97   | 11.5-17.5 g/dL |
| WBC                | 19.5 K  | 4-11 K/µL      |
| Neutrophils        | 11.61%  | 40-75%         |
| Lymphocytes        | 83.09%  | 20-45%         |
| Platelets          | 497     | 150-450 k/µL   |
| ESR                | 88      | 0-20 mm/ 1st hr|
| CRP                | 12      | <0.5 mg/dL     |
| Creatinine         | 0.7     | 0.64-1.2 mg/dL |
| Urea               | 22      | 18-45 mg/dL    |
| ALT                | 73      | 10-50 U/L      |
| Alkaline Phosphatase | 104  | 40-129 U/L   |
| TSH                | 0.005   | 0.3-4.2 mIU/L  |
| T3                 | 5.13    | 0.8-2.0 ng/mL  |
| T4                 | 24.86   | 5.1-14.1 µg/dL |

TABLE 1: Key laboratory values on initial presentation.

ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ALT: Alanine transaminase; TSH: Thyroid-stimulating hormone.

The patient was reassured and discharged home on ibuprofen (400 mg three times a day), prednisone (30 mg daily), and propranolol (40 mg two times a day). On subsequent reviews, the patient’s symptoms, signs, and thyroid function tests (TFTs) gradually improved. The patient was taken off the ibuprofen, and the dose of prednisone was gradually tapered over the next seven weeks. Seven weeks after the initial presentation, the patient’s TFTs returned to normal and the thyroid swelling completely resolved (Figure 2). Monthly follow-up visits were scheduled for the possible development of hypothyroidism, but the patient’s TFTs remained stable over the next four months.
Discussion

SAT is the most frequent cause of painful thyroiditis [2]. Data suggests that it is caused by viral infections or postviral inflammatory responses. Many patients have a recent history of upper respiratory tract infection. Many viruses, including coxsackievirus, measles, and mumps, have been implicated in the development of SAT [4]. Since the beginning of the COVID-19 pandemic more than two years ago, many extrapulmonary manifestations of the disease, including endocrinological manifestations have been recognized. The first case of SAT secondary to COVID-19 was reported by Brancatella A et al. in early 2020 [5]. Ever since then, multiple cases of COVID-19 associated SAT have been reported from around the world. Most of these cases have been reported to occur either during the active infection or within a few weeks after the recovery. We add to the existing literature by reporting a case from Pakistan, with emphasis on the fact that symptoms and signs of hyperthyroidism in these patients can easily be mistaken as "COVID anxiety". Severe anxiety and other psychiatric disorders have been reported in patients recovering from COVID-19 [6]. Since anxiety and hyperthyroidism share many clinical features, the diagnosis of SAT can easily be missed in these patients. Our patient was first discharged home with the reassurance that the symptoms were due to "COVID anxiety", and will subside soon.

For COVID-19 to invade human cells, the presence of an angiotensin-converting enzyme 2 (ACE2) receptor is essential. The thyroid gland has been shown to express a significant amount of ACE2 receptors [7]. However, there is no evidence to suggest that direct viral invasion of the gland is the cause of SAT. Instead, a more likely explanation is that the inflammatory reaction to viral infections results in the activation of cellular
host responses that then damage thyroid follicular cells [8].

Management of SAT includes alleviation of pain and inflammation with non-steroidal anti-inflammatory drugs (NSAIDs) and steroids [9, 10]. Patients with symptomatic hyperthyroidism also need treatment with a beta-blocker such as propranolol or atenolol.

Conclusions
While reviewing patients with COVID-19 and anxiety, we must be mindful of the possibility of hyperthyroidism secondary to SAT, as it is easy to confuse symptoms of hyperthyroidism with anxiety. As the diagnosis of SAT is primarily clinical and timely recognition and prompt treatment can help alleviate most of the patient’s symptoms, a thorough history and physical examination are of paramount importance.

Appendices

Patient’s Perspective

I thought I was dying of this new virus. It was as if my heart wanted to come out of my chest. After the medications, I started to feel much better. I am thankful to God and the doctors.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Lazarus JH: Silent thyroiditis and subacute thyroiditis. The Thyroid: A Fundamental and Clinical Text. Braverman LE, Utiger RD (ed): Lippincott Williams & Wilkins, Philadelphia; 1996. 577.
2. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ: Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003, 88:2100-2105. 10.1210/jc.2002-021799
3. Nishihara E, Ohuye H, Amino N, et al.: Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med. 2008, 47:725-729. 10.2169/internalmedicine.47.0740
4. DesaiLOUD R, Hofer D: Viruses and thyroiditis: an update. Virol J. 2009, 6:5. 10.1186/1743-422X-6-5
5. Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F: Subacute thyroiditis after Sars-COV-2 infection. J Clin Endocrinol Metab. 2020, 105:2367-2370. 10.1210/clinem/dgaa276
6. Driscoll M, Gu J: Severe anxiety post-COVID-19 infection. Case Rep Psychiatry. 2021, 2021:9922508. 10.1155/2021/9922508
7. Li MY, Li L, Zhang Y, Wang XS: Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020, 9:45. 10.1186/s40249-020-00662-x
8. Kojima M, Nakamura S, Oyama T, Sugihara S, Sakata N, Masawa N: Cellular composition of subacute thyroiditis. An immunohistochemical study of six cases. Pathol Res Pract. 2002, 198:833-837. 10.1078/0344-0372-00544
9. Benhassat CA, Olchovsky D, Tsunov G, Shimon I: Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest. 2007, 30:631-635. 10.1007/BF03534742
10. Arao T, Okada Y, Torimoto K, Kurozumi A, Narisawa M, Yamamoto S, Tanaka Y: Prednisolone dosing regimen for treatment of subacute thyroiditis. J UOEH. 2015, 37:105-110. 10.7888/jueh.37.103